|

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

RECRUITINGPhase 1Sponsored by University of Wisconsin, Madison
Actively Recruiting
PhasePhase 1
SponsorUniversity of Wisconsin, Madison
Started2025-03-07
Est. completion2026-03
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06122610

Summary

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor

Exclusion Criteria:

* Unable to lie flat during or tolerate PET/CT or SPECT/CT
* Known incompatibility to CT. SPECT, or PET scans
* Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study

Conditions3

CancerNeuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor

Locations1 site

University of Wisconsin - Madison
Madison, Wisconsin, 53705

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.